← SynDRA
ASP-3026
SynDRA canonical compound SYN0038282 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | ALK |
|---|
| Mechanism of action | ALK tyrosine kinase receptor inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- ALK INHIBITOR
- ALK tyrosine kinase receptor inhibitor
- ALK MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- CAMKK2
- STK10
- SLK
- SIK2
- ROS1
- DDR1
- PTK6
- PTK2B
- PTK2
- EGFR
- PRKD2
- EPHB3
- PLK4
- ERN1
- FER
- FES
- FLT3
- FRK
- FYN
- GAK
- GTPBP4
- HCK
- IGF1R
- NQO2
- INSR
- LCK
- LIMK1
- LIMK2
- LTK
- ABL1
- SYK
- EPHA2
- TNK2
- CAMK2D
- TNK1
- CAMK2G
- YES1
- AURKB
- TEC
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ALAT2
- ATXN2
- EML4
- IFNB1
- KSYK
- NPM1
- NSD2
- TP53
Cross-references
Synonyms
- ASP3026
- ASP 3026
- N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine
- UNII-HP4L6MXF10
- HP4L6MXF10
- 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine
- MGGBYMDAPCCKCT-UHFFFAOYSA-N
- MLS006011176
- GTPL7740
- SCHEMBL2827739
- CHEMBL3545360
- C29H40N8O3S
- QCR-144
- EX-A140
- DTXSID90149038
- AOB6601
- MolPort-028-720-342
- BCP06436
- 2229AH
- ZINC68120928
- s8054
- CHEBI:167650
- RefChem:114603
- ALK INHIBITOR ASP3026
- DTXCID7071529
- MFCD21609265
- F6O
- orb1306963
- SCHEMBL29354559
- SCHEMBL30090555
- SCHEMBL31142530
- ASP 3026 [WHO-DD]
- GLXC-05572
- HMS3673C17
- ASP3026?
- XTB91715
- NSC765865
- NSC799336
Look up ASP-3026 in the interactive SynDRA portal →